KYMR compared with ALKS: revenue, margins and what each company keeps, and the suppliers and customers both name

KYMRKymera Therapeutics, Inc.

Mkt capRevenueRevenue

ALKSAlkermes plc.

Mkt capRevenueRevenue

Compare

KYMRKymera Therapeutics, Inc.

ALKSAlkermes plc.

Price

Mkt cap

Revenue

Revenue flow Supply chain Price Co-movers Event sensitivity Earnings history

Save comparison

Earnings history

News Findings Companies A–Z Pricing Methodology Sources Corrections About Terms

Not investment advice. Not a broker-dealer. Indices shown as ETF proxies. Supply-chain data CC BY 4.0; market data not redistributable.

Listed on One’s Vibe · live-checked · Oct ’26

Desk News Calendar Saved

Earnings history

last 4 reports each · paired by recencyMethod ›

KYMR

0 of 4at or beyond implied

Reportimpliedrealized× implied

Q3 FY26±18.2%▲+0.07%×0.01

Q2 FY26±10.4%▲+1.04%×0.10

Q1 FY26±10.3%▼−0.54%×0.05

Feb 26 '26±11.8%▲+4.80%×0.41

ALKS

0 of 4at or beyond implied

Reportimpliedrealized× implied

Q3 FY26±7.3%▲+1.78%×0.25

Q2 FY26±9.8%▼−4.23%×0.43

= impliedKYMR realized, solidALKS realized, hatchedOne scale, both sides: full bar = 19%× = |realized| ÷ impliedSource: market data

May 5 '26

±7.3%

▲+6.09%

×0.84

Q1 FY26±8.6%▼−7.04%×0.81

KYMRKymera Therapeutics, Inc.

131.73▲+2.82%· post 131.73

Mkt cap$11.2BRevenue$65MQ2 FY26Revenue$39MFY25

ALKSAlkermes plc.

45.88▲+3.01%· post 45.88

ClosedNov 6 '26

Mkt cap$7.7BRevenue$480MQ3 FY26Revenue$1.5BFY25

Compare

ClosedNov 6 '26

KYMRKymera Therapeutics, Inc.

ALKSAlkermes plc.

131.73▲+2.82%post 131.73

Price

45.88▲+3.01%post 45.88

$11.2B

Mkt cap

$7.7B

Q2 FY26$65M

Revenue

$480MQ3 FY26

FY25$39M

Revenue

$1.5BFY25

KYMR131.73▲+2.82%vsALKS45.88▲+3.01%ClosedNov 6 '26